| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
76,182,000 |
| Market
Cap: |
13.21(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$127.77 - $330.23 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Instruments & Supplies |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 882 |
| Guru Rank Value : 0.1 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Insulet is primarily engaged in the development, manufacture and sale of its proprietary Omnipod® System, a continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System includes: the Omnipod Insulin Management System and the Omnipod DASH™ Insulin Management System, its digital mobile Omnipod platform. The Omnipod System features: a small, self-adhesive disposable tubeless Omnipod device (Pod) that the user fills with insulin and wears directly on the body; and the Personal Diabetes Manager, a wireless, handheld device that programs the Pod with the user's personalized insulin-delivery instructions and, wirelessly monitors the Pod's operation.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
5,551 |
8,851 |
| Total Buy Value |
$0 |
$0 |
$1,006,995 |
$2,012,670 |
| Total People Bought |
0 |
0 |
2 |
3 |
| Total Buy Transactions |
0 |
0 |
2 |
3 |
| Total Shares Sold |
3,660 |
15,341 |
51,904 |
164,922 |
| Total Sell Value |
$662,699 |
$2,568,947 |
$8,774,318 |
$39,699,166 |
| Total People Sold |
2 |
3 |
5 |
8 |
| Total Sell Transactions |
2 |
4 |
8 |
21 |
| End Date |
2024-03-09 |
2023-12-07 |
2023-06-08 |
2022-06-08 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Levangie Daniel J |
President, Drug Delivery |
• • – |
2016-03-09 |
4 |
OE |
$15.14 |
$235,351 |
D/D |
15,545 |
25,358 |
|
- |
|
| Levangie Daniel J |
President, Drug Delivery |
• • – |
2016-03-07 |
4 |
S |
$31.15 |
$238,702 |
D/D |
(7,663) |
9,813 |
|
- |
|
| Hopfield Jessica |
Director |
• • – |
2016-03-02 |
4 |
B |
$30.91 |
$99,839 |
D/D |
3,230 |
8,838 |
2.39 |
- |
|
| Spears Michael P |
SVP, Quality and Regulatory |
• • – |
2016-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
10,253 |
32,684 |
|
- |
|
| Colleran David |
SVP, Secretary and GC |
• • – |
2016-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
6,835 |
28,462 |
|
- |
|
| Sullivan Patrick J |
President & CEO |
• • – |
2016-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
42,720 |
172,795 |
|
- |
|
| Levitz Michael L |
SVP and CFO |
• • – |
2016-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
10,253 |
53,281 |
|
- |
|
| Thomas Bradley A |
EVP Human Resources |
• • – |
2016-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
10,253 |
47,424 |
|
- |
|
| Thomas Bradley A |
EVP Human Resources |
• • – |
2016-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
6,813 |
37,171 |
|
- |
|
| Petrovic Shacey |
President, Diabetes Products |
• • – |
2016-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
6,813 |
58,162 |
|
- |
|
| Sullivan Patrick J |
President & CEO |
• • – |
2016-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
45,648 |
130,075 |
|
- |
|
| Levangie Daniel J |
President, Drug Delivery |
• • – |
2016-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
6,813 |
17,476 |
|
- |
|
| Petrovic Shacey |
CCO |
• • – |
2016-02-09 |
4 |
D |
$26.00 |
$164,528 |
D/D |
(6,328) |
51,349 |
|
- |
|
| Lemoine David A |
Director |
• • – |
2016-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
6,410 |
6,410 |
|
- |
|
| Alpuche Charles |
SVP, Global Manufacturing |
• • – |
2016-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
16,021 |
16,021 |
|
- |
|
| Thomas Bradley A |
EVP Human Resources |
• • – |
2015-12-01 |
4 |
D |
$37.27 |
$73,534 |
D/D |
(1,973) |
30,358 |
|
- |
|
| Thomas Bradley A |
EVP Human Resources |
• • – |
2015-08-20 |
4 |
B |
$29.41 |
$24,851 |
D/D |
845 |
32,331 |
2.74 |
- |
|
| Hopfield Jessica |
Director |
• • – |
2015-07-27 |
4 |
A |
$0.00 |
$0 |
D/D |
5,608 |
5,608 |
|
- |
|
| Colleran David |
Secretary and General CounselO |
• – – |
2015-07-20 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
21,627 |
|
- |
|
| Sullivan Patrick J |
President & CEO |
• • – |
2015-06-05 |
4 |
B |
$29.39 |
$293,880 |
D/D |
10,000 |
83,650 |
2.81 |
- |
|
| Sullivan Patrick J |
President & CEO |
• • – |
2015-05-28 |
4 |
B |
$27.74 |
$558,170 |
D/D |
20,000 |
73,650 |
2.81 |
- |
|
| Scannell Timothy J |
Director |
• • – |
2015-05-15 |
4 |
B |
$27.05 |
$94,675 |
D/D |
3,500 |
12,120 |
2.81 |
- |
|
| Scannell Timothy J |
Director |
• • – |
2015-05-13 |
4 |
A |
$0.00 |
$0 |
D/D |
4,039 |
8,620 |
|
- |
|
| Zakrzewski Joseph S |
Director |
• • – |
2015-05-13 |
4 |
A |
$0.00 |
$0 |
D/D |
4,039 |
24,039 |
|
- |
|
| Sommer Regina O |
Director |
• • – |
2015-05-13 |
4 |
A |
$0.00 |
$0 |
D/D |
4,039 |
24,539 |
|
- |
|
1137 Records found
|
|
Page 25 of 46 |
|
|
3.15 (1.85%) 
